With the integration of artificial intelligence (AI) and machine learning (ML) in the drug discovery realm, Terray Therapeutics’ goal is simple: accurate data from repeatable iterations of small molecule screens against a desired target. Terray uses DNA Encoded Libraries (DEL) to obtain billions of data points with our proprietary high-throughput screening platform. The generated data is then fed into our AI and ML engines to generate further small molecule iterations for additional testing. Our company has been able to utilize Agilent’s unique platform of modular devices to allow us to automate the building of our libraries, resynthesize targeted small molecules, purify the resynthesized compounds, generate biochemical IC50s, then automate our cellular assays to help drive our next generation AI platform. Utilizing automated systems allows us to eliminate much of the human error components of the synthesis process. By removing those human elements, where possible, we have achieved a more consistent and repeatable process. The major elements we employ for this are modular components, redundant systems, and the invaluable collaboration with Agilent’s service engineers and specialists. Leveraging the current automation technology, we are now able to generate information at a scale which eclipses our original manual methods improving our AI and ML engines; Agilent’s NGS and SRT Bravo liquid handlers are one such tool. Agilent’s modular approach to NGS workflows and the life sciences have allowed our team of engineers to build a robust set of unique platforms where we can automate the focus on the science.
.png)
